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A panel of 16 monoclonal antibodies recognizing M protein (MI) of influenza virus was generated.
Competition analyses resulted in localization of 14 monoclonal antibodies to three antigenic sites. Three
monoclonal antibodies localized to site lB recognized a peptide synthesized to Ml (residues 220 to 236) with
enzyme-linked immunosorbent assay titers equivalent to or greater than that seen with purified Ml; therefore,
site lB is located near the C terminus of Ml. Sites 2 and 3 localize to the N-terminal half of Ml. Antigenic
variation of M proteins was seen when the monoclonal antibodies were tested against 14 strains of type A
influenza viruses. Several monoclonal antibodies showed specific recognition of AIPR/8/34 and A/USSR/90/77
M proteins and little or no reactivity for all other strains tested. Immunofluorescence analysis with the
monoclonal antibodies showed migration of M protein to the nucleus during the replicative cycle and
demonstrated association of M protein with actin filaments in the cytoplasm. Use of a vaccinia virus
recombinant containing the M-protein gene demonstrated migration ofM protein to the nucleus in the absence
of synthesis of gene products from other influenza virus RNA segments.
M protein (Ml) of influenza virus has an important struc-
tural role in the virion. It is located on the interior side of the
lipid bilayer, forming a shell which surrounds the nucleocap-
sid (37). However, its functional role in the viral replicative
cycle remains elusive. The only biological activity demon-
strated for M protein has been its ability to inhibit the
polymerase of influenza virus, possibly modulating viral
replication (45, 46). Complete removal of M protein from the
polymerase complex results in greatly enhanced polymerase
activity (17).
The significance of M protein in immunity to influenza
virus is also uncertain. After immunizing mice with M
protein, Webster and Hinshaw (43) did not find that the mice
were protected after challenge, but they did observe en-
hanced clearance of virus from the lungs of mice after
infection, suggesting involvement of cellular immunity to M
protein. An epitope for recognition ofM protein by cytotoxic
T cells has been demonstrated elsewhere (13). Significant
levels of antibodies to M protein are found after influenza
virus infection or influenza virus vaccination in clinical
studies (18).
van Wyke and co-workers (40) reported on three mono-
clonal antibodies recognizing distinct epitopes for M protein.
Ye and colleagues (45) found significant reversal of tran-
scriptase inhibition produced by M protein with one of these
monoclonal antibodies. Hankins and co-workers (Virus
Genes, in press) have demonstrated reversal of M protein
transcriptase inhibition with monoclonal antibodies from the
panel described in the current report.
In this work, we report on an extensive panel of 16
hybridoma lines producing monoclonal antibodies reactive
with M protein. These monoclonal antibodies were capable
of recognizing antigenic differences among various strains of
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type A influenza viruses. The use of synthetic peptides and
comparative sequence analysis permitted localization of
three antigenic sites to specific amino acids or peptide
segments of M protein. The monoclonal antibodies permit-
ted analysis of intracellular localization of M protein during
viral infection.
MATERIALS AND METHODS
Preparation of M protein. M protein was purified from
outdated swine influenza vaccine (X-53a recombinant virus
strain containing the A/PR/8/34 M-protein gene [3, 19]) by
sodium dodecyl sulfate gel chromatography (5-7). Purity
was verified by sodium dodecyl sulfate gel electrophoresis as
described earlier (12). M protein was exhaustively dialyzed
against distilled water for several days at 4°C to remove
sodium dodecyl sulfate, with resultant formation of aggre-
gated M protein.
Production of monoclonal antibodies reactive with M pro-
tein. BALB/c mice were immunized with 10 to 25 p.g of
purified M protein in Freund complete adjuvant. Mice were
subsequently given an intravenous booster dose of 10 to 25
jig of M protein 6 weeks to 3 months later. The spleens were
removed 3 days after the booster dose, and the spleen cells
were fused, using polyethylene glycol with SP2/0-Agl4,
nonsecreting myeloma cells (ATCC CRL 1581) which were
growing in log phase (20). Hybridomas were selected in HAT
medium and screened for reactivity by enzyme-linked im-
munosorbent assays (ELISA) on microtiter plates coated
with M protein as described below. Reactive hybridomas
were cloned at 0.5 and 1 cell per well in 96-well microplates
with T-cell feeder layers. Monoclonal antibodies were iso-
typed by use of the Boehringer-Mannheim isotyping kit.
Ascitic fluids were prepared from all hybridoma lines in
BALB/c mice which had been previously primed with pris-
tane.
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Hybridoma lines M2-1C6, 289/4, and 904/6, previously
described by van Wyke and co-workers (40), were gener-
ously supplied by Kathleen van Wyke Coelingh. 289/4 and
904/6 were subsequently cloned in our laboratory to produce
289/4-D5 and 904/6-D5.
Preparation of virus. Pools of virus were prepared in
monolayers of MDCK cells for 14 different strains of type A
influenza viruses; one type B influenza virus strain was
prepared in ovo. Virus strains X-53a (3, 19), A/PR/8/34,
A/WSN/33, A/Sing/1/57, A/Aichi/2/68, A/Udorn/307/72, A/
Pt. Chalmers/1/73, A/Texas/1/77, A/Bangkok/lM9, and B/
Lee/40 were obtained from E. D. Kilbourne. A/FM/1/47,
A/FW/1/50, and A/USSR/90/77 were obtained from Alan
Kendal and Nancy Cox. A/Mallard/NY/6750/78 and A/Duck/
Ukraine/1/63 were supplied by Virginia Hinshaw.
Viruses were propagated in MDCK cell monolayers in
minimum essential medium (GIBCO Laboratories) contain-
ing 2 ,ug of trypsin (VMF; Worthington Diagnostics) per ml
for 3 days after inoculation with virus at 103 (50% egg
infectious doses). Type B influenza virus was replicated in
10-day-old embryonated eggs. Cellular debris was removed
by centrifugation at 4,068 x g for 15 min. Virus was purified
by centrifugation at 47,800 x g for 60 min. Virus was further
purified by centrifugation of the pellet to the interface of a 30
to 60% discontinous sucrose gradient at 90,440 x g for 60
min. Sucrose was removed by diluting the virus in phos-
phate-buffered saline (PBS) and centrifuging at 57,881 x g
for 60 min. Protein concentration was determined by the
assay of Lowry et al. (23).
Antigenic analysis of M protein and peptides by ELISA.
ELISA was performed as described earlier by Khan and
co-workers (18) with the following modifications. Microtiter
plates were coated with M protein (40 ng per well), purified
virus (100 ng per well), peptides (1 Vig per well), or synthetic
peptides conjugated to various carrier proteins (1 p.g per
well) for 72 h. After coating with 0.5% bovine serum albumin
in PBS-Tween 20, ascitic fluids were diluted in serial three-
fold dilutions across the plate, beginning with an initial
dilution of 1:100. Sheep anti-mouse alkaline phosphatase
conjugate (Sigma Chemical Co.) was added to quantitate
bound monoclonal antibody and p-nitrophenyl phosphate
was employed as a substrate. Endpoint titrations were
determined as the dilution which produced an absorbance
value threefold above background. ELISA titers were deter-
mined for all monoclonal antibodies against a single virus
strain on a given day with assays performed in duplicate.
Western blot (immunoblot). The specificity of monoclonal
antibodies for M protein was confirmed by Western blot
analysis. The protocol followed was that of the Promega-
Biotec system, utilizing alkaline phosphatase-conjugated
second antibody with a precipitating substrate.
Antigenic site localization by competitive inhibition analysis.
Monoclonal antibodies were purified from ascitic fluids by
chromatography on a column (90 by 2.5 cm) containing ACA
34 Ultrogel (LKB Instruments, Inc.) in PBS containing
0.05% sodium azide. Purified monoclonal antibodies were
conjugated with alkaline phosphatase by the protocol de-
scribed by Voller et al. (41). Microtiter plates were coated
with 40 ng of M protein per ml, blocked, and washed as
described earlier (18). Test unlabeled monoclonal antibody
was diluted in twofold steps across the microtiter plate and
allowed to react with M protein. Conjugated monoclonal
antibody was added at a dilution sufficient to produce color
development of 0.25 to 0.60 A410 unit after 30 min of
incubation. The blocking activity of unlabeled monoclonal
antibody was assessed.
TABLE 1. Amino acid sequences of peptides synthesized
for M-protein AIPR18134"
Pep-
tide Amino acid sequence
no.
66 78
1 L T V P S E R G L Q R R R
83 100
2 A L N G N G D P N N M D K A V K L Y
104 118
3 K R E I T F H G A K E I S L S
152 166
4 E Q I A D S Q H R S H R Q M V
220 231 236
5 G T H P S S S A G L K N D L L E N
"Sequence data taken from Winter and Fields (44).
Synthetic peptides. Peptides were synthesized to segments
of M protein on the basis of the A/PR/8/34 M-protein
sequence reported by Winter and Fields (44). Peptide seg-
ments likely to be immunoreactive were selected on the
basis of analysis of M-protein structure by utilizing the
hydropathicity values of Kyte and Doolittle (21) and a
moving-segment approach to continuously determine aver-
age hydropathicity within a 7-residue segment as it advances
through the sequence. Predictions of secondary structure
were also made from the Chou-Fasman algorithm (9). Con-
sideration was also given to the findings of Rothbard and
co-workers (34), by selecting regions which have both hy-
drophobic and hydrophilic characteristics. Selected peptides
included sequences within hydrophilic domains that in-
cluded beta-turns or proline-containing junctions between
hydrophilic and hydrophobic domains where the protein was
likely to turn and expose corners.
Selected peptides included those containing residues 66 to
78 (peptide 1), 83 to 100 (peptide 2), and 152 to 166 (peptide
4) (Table 1). Two additional peptides containing residues 104
to 118 (peptide 3) and 220 to 236 (peptide 5) were selected for
synthesis on the basis of shared reactivity of monoclonal
antibodies with M proteins of known sequence (Table 1).
Peptides were synthesized on a Beckman model 990C pep-
tide synthesizer using solid-phase techniques (10). The pep-
tides were purified by chromatography on Sephadex LH-20,
followed by high-pressure liquid chromatography utilizing a
Vydac C18 column (15 to 20 ,um).
Peptides were conjugated to carrier protein keyhole limpet
hemocyanin, bovine serum albumin, or thyroglobulin by the
protocol described by Atassi and co-workers (2). Reactivity
of monoclonal antibodies with peptide segments was deter-
mined by ELISA after coating of microtiter plates with
conjugated or free peptides at 1 p.g per well as described
above.
Construction of vaccinia virus recombinant vP273, express-
ing the influenza virus M protein. A vaccinia virus promoter
from the HindlIl I fragment (33), corresponding to the 13L
early/late promoter reported by Schmitt and Stunnenberg
(36), was inserted in a right-to-left orientation into flanking
vaccinia virus arms between the leftmost EcoRI and BglII
sites of HindIII-F, generating plasmid pMP47PP. This region
of vaccinia virus has been shown to be nonessential for virus
replication (32) and has recently been shown to be located
within the coding region of the small subunit for ribonucle-
otide reductase (38).
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FIG. 1. Western blot analysis of X-53a (HlNl) virus (V) (1.0 jig
per well) or M protein (M) (0.25 p.g per well) after electrophoresis
and electrophoretic transfer under nonreducing conditions. Nitro-
cellulose strips were incubated with the following antisera or ascitic
fluid preparations: anti-A/PR/8/34 (H1N1) virus (a) or monoclonal
antibody 2BB10-G9 (b), 1GII-D1l (c), or 611-G10-D3 (d). The strips
were developed as described in the Western blot protocol.
A 1,030-base-pair EcoRl fragment containing the gene
coding for the influenza virus M protein was isolated from
pAPR701 (generously provided by P. Palese, Mt. Sinai
School of Medicine, New York, N.Y.) and cloned down-
stream from the promoter in pMP47PP, generating
pSD47PPMA. pSD47PPMA was recombined into VTK-79
vaccinia virus by marker transfer (29), generating vP273.
Immunofluorescence analysis. CV-1 cells (ATCC CCL70)
were cultivated on cover slips and infected at a multiplicity
of infection of 1:1 to 1:10 (PFU/cell). After infection for 3 to
5 h, the cells were fixed with 3.75% paraformaldehyde in
PBS for 15 min, followed by permeabilization with 0.15%
Triton X-100 in PBS for 8 min (D. Kohtz, personal commu-
nication; also modified from Peeples [31]). The cover slips
were washed with PBS and exposed to ascitic flLids pre-
pared from various hybridoma lines or to antisera diluted at
1:50 to 1:100. Antisera or ascitic fluids were absorbed with
uninfected cells before use to eliminate nonspecific staining.
Gloat or sheep anti-mouse immunoglobulin G (IgG) conju-
gated to fluorescein or rhodamine (Organon Teknika) was
used to visualize the monoclonal antibody. Rhodamine-
conjugated phalloidin was obtained from Molecuilar Probes.
Infection with the vaccinia recombinant, vP273, was per-
formed at a multiplicity of infection of 1:10 (PFU/cell). Cells
were fixed with paraformaldehyde 3 h postinfection and
processed as described above. Slides were examined with a
Zeiss Axiomat fluorescence microscope equipped with the
appropriate filters.
RESULTS
Characterization of monoclonal antibodies. All monoclonal
antibodies which recognized M protein by ELISA also
recognized M protein as analyzed by Western blotting;
representative blots are shown for three monoclonal anti-
bodies in Fig. 1. The majority of the hybridoma lines
secreted monoclonal antibodies of the IgGl isotype, with the
following three exceptions: 611-B12-D10 secreted IgG2a;
951-D10-B3 secreted IgG2b; and 611-G1O-D3 secreted IgM.
All monoclonal antibodies contained K light chains.
Monoclonal antibodies for all 16 hybridoma lines were
































FIG. 2. Competitive analysis was performed by diluting the
monoclonal antibody across the 12 wells of a microtiter plate. The
wells were previously coated with 40 ng of M protein. Blocking
activity of the monoclonal antibody was observed against 2BB10-
G9, lGll-D1l, or 611-G10-D3 monoclonal antibody conjugated with
alkaline phosphatase and diluted to provide an enzyme activity
capable of cleaving p-nitrophenyl substrate in 1 h to yield approxi-
mately 0.4 A405 unit. BKGD., Background.
petitive inhibition experiments were performed. Each mono-
clonal antibody (unlabeled) was tested for its ability to block
the binding of the remaining 15 monoclonal antibodies
(alkaline phosphatase conjugated) to M protein in ELISA.
On the basis of reciprocal analysis for our panel of 16
monoclc/nal antibodies, we were able to group 14 monoclo-
nal antibodies into three groups. Competition curves repre-
J. VIROL.
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TABLE 2. Antigenic analysis of Ml for various strains of influenza virus'
ELISA titerb (103) to:
Antigenic site HlNl H2N2 H3N2 H3N8
and monoclonal M pro- A/Dck
antibody tein'X"53 A/PR/ A/WSN/ A/FM/ A/FW/ A/USSR/ A/Sing/ A/Mal/ A/Ai A/Ud/ A/PC/ A/Tex/ A/Ban/ A/Duck/
a 8/34 33 1/47 1/50 90/77 1/57 NY/78 2/68 307/72 1/73 1/7 1/79 1/63
1A
2BB10-G9 1,020 368 616 512 200 314 218 622 940 512 350 1,320 600 516 418
lG8-A11 420 492 488 582 106 152 264 650 1,360 642 290 980 608 398 392
3G12-C12 740 478 604 560 62 140 320 640 1,340 1,560 240 1,080 606 262 424
9E8-B2 524 980 1,220 428 438 414 584 465 1,380 1,080 322 1,860 740 544 582
821-B8-A8 306 126 212 346 134 126 118 120 396 460 136 450 360 186 172
1B
2E5-C1 1,500 1,820 1,720 0 0 21 1,750 0 0 0 0 0 0 0 0
961-G8-H3 468 326 474 4 1 24 332 3 5 20 1 7 5 2 2
963-DE-GlO 478 620 496 0 0 9 358 0 0 1 0 0 0 0 0
6B9-B8 108 182 158 0 0 0 82 0 1 0 0 0 1 0 0
2
lGll-Dll 540 740 1,560 558 320 350 558 590 1,940 1,440 578 1,480 1,480 340 598
951-C4-G2 154 172 212 50 24 32 94 330 418 194 94 214 219 91 106
823-D8-B11 322 562 412 0 72 96 190 654 960 560 582 580 560 196 272
M2-lC-6d 48 50 51 41 42 16 21 80 90 70 40 58 84 24 34
289/4-D5d 43 36 43 34 10 15 22 62 78 71 62 56 64 24 41
3
611-G1O-D3 88 68 59 4 6 6 4 72 90 60 3 104 108 5 3
951-D1O-B3 70 46 96 4 1 8 2 162 165 64 16 194 188 16 16
Unclassified
611-B12-D1O 78 126 62 66 52 24 46 500 190 146 138 200 155 44 72
961/6-BlO 294 7 4 1 0 1 2 108 56 2 1 8 8 1 1
940/6-D5d 0 1 1 8 0 4 4 62 24 36 10 28 29 1 19
a See Materials and Methods for description of ELISA protocol and calculation of titers. Each titer is the dilution absorbance value threefold above background
A410 x 103. The ELISA titers of B/Lee/40, influenza type B virus, were 0 for all monoclonal antibodies.
bAbbreviations: A/Mal/NY/78, A/Mallard/NY/6750/78; A/Ai/2/68, A/Aichi/2/68; A/Ud/307/72, A/Udorn/307/72; A/PCI1173, A/Pt. Chalmers/1/73; A/Tex/1/77,
A/Texas/1/77; A/Ban/1/79, A/Bangkok/lM9; A/Duck/1/63, A/Duck/Ukraine/1/63.
Purified from X-53a (A/PR/8/34 M-protein gene).
d Described by van Wyke and co-workers (40).
sentative for each of the three sites are shown in Fig. 2.
Nonreciprocal inhibition was seen between 611-G10-D3 (site
3) and 2BB10-G9 (site 1). 611-B12-D10 and 961/6-BlO did not
compete with any of the 14 monoclonal antibodies assigned
to three antigenic sites and are listed as unclassified; these
may represent an additional two sites as determined by
direct binding with M-protein fragments (Hankins et al., in
press). Our analysis placed two of the monoclonal antibodies
from van Wyke and colleagues (40) in antigenic site site 2;
we were unable to classify the third.
Antigenic analysis with monoclonal antibodies. The mono-
clonal antibody panel was evaluated for reactivity with a
broad panel of influenza viruses (Table 2). Ascitic fluids were
prepared from 16 hybridoma lines produced in our labora-
tory and 3 lines reported by van Wyke and co-workers (40).
Fourteen strains of type A influenza viruses and one strain of
type B influenza virus were tested (Table 2). Fourteen
strains are passaged from the original wild-type isolate; one
strain, X-53a, is a reassortant virus containing the A/PR/8/34
M-protein gene. Three HA and three NA subtypes (type A)
from 12 human isolates and 2 avian isolates are included.
M-gene sequence information is available for six of these
strains: A/PR/8/34 (1, 44), A/USSR/90/77 (35), A/WSN/33 (4,
25), A/Mallard/NY/6750/78 (8), A/Udorn/307/72 (22), and
A/Bangkok/1/79 (27).
Several of the monoclonal antibodies were broadly reac-
tive with M protein from all strains tested; for these mono-
clonal antibodies, differences in reactivity were more likely
due to various antigen concentrations in the viral prepara-
tions than to specificity. Other monoclonal antibodies exhib-
ited marked differences in reactivity among different strains.
None of the monoclonal antibodies showed any level of
recognition of B/Lee/40.
Monoclonal antibodies grouped in antigenic site 1 dis-
played two patterns of reactivity; broad reactivity against all
type A influenza viruses (site 1A) or narrow reactivity (site
1B), recognizing only A/PR/8/34 and A/USSRI90/77. The
most striking feature for antigenic site 2 was the complete
lack of reactivity of 823-D8-B11 with A/WSN/33.
Monoclonal antibodies in antigenic site 3 (611-G1O-D3 and
951-D10-B3) showed substantially better recognition of A/
Aichi/2/68, A/Pt. Chalmers/1/73, and A/Texas/1/77 (H3) with
lower recognition of A/Udorn/307/72 and A/Bangkok/1/79,
with the degree of recognition unrelated in any sequential
way to the year of virus isolation. This pair of monoclonal
antibodies also reacted at high dilution with H2 strains and
with A/PR/8/34 (H1) and reacted only at low dilution with
other Hi viruses.
Generally, monoclonal antibodies had similar titers when
tested against purified M protein or total virus. The excep-
tion was 961/6-BlO (unclassified) which had a titer of 294,000
versus M protein (purified from X-53a) and titers of only
4,200 and 7,000 versus A/PR/8/34 and X-53a, respectively.
However, 961/6-B10 was capable of recognizing this epitope
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FIG. 3. (a) Relative hydrophilicity within the M-protein sequence of the A/PR/8/34 (APR34M) strain of influenza virus. The relative
hydrophilicity was calculated by a moving-segment average over 7 residues, using the values assigned by Kyte and Doolittle (21). Positive
values correspond to the hydrophilic regions. (b) Secondary structure of M protein of influenza virus strain AIPRI8134.
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TABLE 3. Reactivity of monoclonal antibodies
with synthetic peptides
ELISA titer" (103) to:
And tmonoc sot Peptide 2 Peptide 5




2BB10-G9 - - - - -
1G8-A11 - - - 0.4 -
3G12-C12 - - - 0.6 -
9E8-B2 - - - 0.4 -
821-B8-A8 - - - - -
1B
2E5-C1 - - 0.9 270.0 200.0
961-G8-H3 - - - - -
963-D3-G10 - - - 68.0 5.4
6B9-B8 - - 1.4 1,100.0 28.0
2
lG1l-D1l - 0.5 0.7 0.3 -
951-C4-G2 1.6 1.0 - - -
823-D8-B11 - - - - -
M2-1C6 - - - - -
289/4-D5 - - - - -
3
611-G10-D3 - 0.5 0.3 - 0.3
951-D10-B3 3.4 2.2 - - -
Unclassified
611-B12-D10 - - - - 0.3
961/6-BlO - - - - -
904/6-D5 ND ND - - -
" KLH-conjug., Keyhole limpet hemocyanin-conjugated; BSA-conjug., bo-
vine serum albumin-conjugated; thyro-conjug., thyroglobulin-conjugated;-.
titer of <0.3 x 103; ND, not done.
in two H2N2 viruses, A/Sing/1/57 and A/Mallard/NY/6750/
78, with titers of 108,000 and 56,000, respectively.
M-protein peptides and reactivity with monoclonal antibod-
ies. The hydropathicity analysis for M protein is shown in
Fig. 3a. Hydrophilic and hydrophobic regions are well-
defined for M protein. The major hydrophilic domains are
represented by peaks 75, 88, 92, 103, and 161. The N
terminus is hydrophobic. In contrast to similar analysis
performed on neuraminidase, the M-protein molecule is
mainly alpha-helical, with few beta-sheets and beta-turns
(Fig. 3b). Peptide 1 (residues 66 to 78) includes the hydro-
philic domain (peak 75); it contains a beta-turn and a proline
residue. Peptide 2 (residues 83 to 100) includes the hydro-
philic domain containing peaks 88 and 92. Peptide 3 (residues
104 to 118) includes a hydrophilic region (peak 103). Peptide
4 (residues 152 to 166) includes a hydrophilic region (peak
161) and contains a beta-turn. Peptide 5 (residues 220 to 236)
includes a hydrophilic region with a proline residue and
beta-turns.
Monoclonal antibodies in antigenic sites 2 and 3 both
showed some reactivity with peptide 2 when this peptide was
utilized as an adsorbent in ELISA (Table 3). Reactivity was
observed for 951-D10-B3 (site 3) and 951-C4-G2 (site 2) when
either free or conjugated peptide was used as an adsorbent.
Lower titers were found for lG1l-Dll (site 2) and 611-
G10-D3 (site 3). Little or no reactivity was found for peptide
1 (free), 3 (free or conjugated), or 4 (free or conjugated) with
any of the monoclonal antibodies (data not shown).
Peptide 5 (residues 220 to 236) was synthesized after
analysis of the sequences of M proteins reported in the
literature for a shared residue(s) which could account for the
high ELISA reactivity observed with AIPR/8/34 and A/
USSR/90/77 and the absence of reactivity (or low reactivity)
found for all other strains. Among viral strains analyzed in
Table 2 for which complete sequence information is avail-
able, it was found that A/PR/8/34 and A/USSR/90/77 share an
asparagine residue at position 231; M proteins from all other
strains of known sequence have aspartic acid at this posi-
tion. Results obtained with peptide 5 as an adsorbent in
ELISA analysis are dramatic (Table 3). Peptide 5, when
conjugated to bovine serum albumin or thyroglobulin and
used as an ELISA adsorbent, produced titers up to 10-fold
greater than that seen with purified M protein for three of
four monoclonal antibodies grouped in antigenic site 1B in
Table 2.
Immunofluorescence analysis. Monoclonal antibodies to M
protein representing each antigenic site produced distinct
nuclear staining of infected cells 5 h after infection. Fluores-
cence was clearly intranuclear, rather than associated with
the nuclear membrane, as demonstrated by focusing through
various planes of the nuclei (Fig. 4). Faint cytoplasmic
staining was seen at 3.5 h. The nucleoli appeared to be more
heavily stained than the nucleus, unlike the pattern seen for
.f
FIG. 4. Immunofluorescence visualization of M protein in influ-
enza virus (X-53a)-infected CV-1 cell monolayers at 5 h postin-
fection. Visualization was performed with lG1l-D1l monoclonal
antibody, followed by the addition of fluorescein-conjugated goat
anti-mouse antibody. Arrows indicate nucleoli. Magnification,
x400. Same conditions for both upper and lower panels.
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FIG. 5. Immunofluorescence visualization of nucleoprotein in
influenza virus (X-53a)-infected CV-1 cell monolayers at 5 h postin-
fection. Visualization was performed with monoclonal antibody to
nucleoprotein, followed by the addition of fluorescein-conjugated
goat anti-mouse antibody. Magnification x400.
immunofluorescence localization with nucleoprotein in
which the nucleoli were void of fluorescence (Fig. 5). M
protein was also seen to colocalize with the actin filaments in
infected cells, as demonstrated by staining with rhodamine-
conjugated phalloidin and monoclonal antibodies to M pro-
tein (fluorescein-conjugated second antibody) (Fig. 6a and
b).
CV-1 cells infected with the vaccinia virus recombinant
vP273 showed intense production ofM protein after only 3 h
(Fig. 7). M protein was seen in the cytoplasm in association
with cytoplasmic factories of vaccinia virus production as
well as in the nucleus. More intense staining of the nucleoli
was observed. Vaccinia virus antigens were not seen in the
nucleus. Phalloidin staining demonstrated the disaggregation
of actin filaments in the vaccinia virus-infected cells (Fig. 8).
DISCUSSION
Antigenic variation among M proteins. The monoclonal
antibody panel to M protein permits us to distinguish several
unique antigenic features of M protein among different
influenza virus strains, some quite dramatically. Several
monoclonal antibodies were developed which are capable of
recognizing A/PR/8/34 and A/USSR/90/77 but which show
little or no recognition of other strains, including Hl strains
from the earlier Hl epoch, such A/FMI/147 and A/FW/1/50.
823-D8-Bll (antigenic site 2) is unable to recognize A/
WSN/33.
The lack of reactivity of 961/6-BlO (unclassified) with M
protein in whole-virus preparations of A/PR18134 and other
strains may be a result of steric hindrance. Evaluation of
additional H2N2 and H2N(1 through 9) strains may help
determine if this phenomenon of recognition ofM protein in
H2N2 strains is related to the hemagglutinin.
The breadth and variation of reactivity of the monoclonal
antibody panel to M protein of different viral strains provides
a valuable tool for thorough antigenic analysis ofM proteins.
As new virus variants appear, screening for antigenic varia-
tion with this panel will suggest M-protein genes of interest
for sequence analysis or may demonstrate reassortment for
the M gene in isolates. This panel will permit antigenic
analysis ofM protein of new isolates in addition to antigenic
analysis of the surface components, hemagglutinin and neur-
aminidase. Variation in reactivity with different monoclonal
antibodies permits genetic analysis of the M-protein gene
after reassortment of influenza viruses in the laboratory (16a)
or in epidemiologic studies of wild-type strains.
Localization of antigenic sites with synthetic peptides and
comparative sequence analysis. Since M protein is highly
conserved with only a few amino acid differences among M
proteins derived from different strains, analysis of sequence
data for M protein in parallel with analysis of reactivity
patterns in ELISA allows us to draw some conclusions about
localization of antigenic sites within M protein.
The narrowly reactive subset of monoclonal antibodies to
antigenic site 1 demonstrates a shared epitope between
AIPR/8134 and A/USSR/90/77 which differs from all other
strains examined. Analysis of sequence data for a residue(s)
common to A/PR18134 and A/USSR/90/77 and differing from
all other strains with known sequences shows only one
common residue at position 231 at which A/PR/8/34 and
A/USSR/90/77 have an asparagine residue; A/WSN/33, A/
Mallard/NY/6750/78, A/Udorn/307/72, and A/Bangkok/1/79
have aspartic acid at this position. Synthesis of peptide 5
(residues 220 to 236) containing asparagine at residue 231
and use of this peptide as an adsorbent in ELISA resulted in
strong recognition by at least three of the monoclonal
antibodies localized to antigenic site 1B. Since the synthetic
peptide was recognized by monoclonal antibodies resulting
in titers equivalent or higher than that seen when M protein
or M protein in virus is used as an ELISA adsorbent, it is
likely that this region represents a linear epitope involving
residue 231. This region appears to be a significant B-cell
recognition site, with at least 3 of 16 hybridoma lines (Table
3) showing high reactivity with this site.
The ELISA reactivity for peptide 5 also demonstrates the
importance of conjugating peptides to carriers for analyzing
reactivity of peptides with monoclonal antibodies. Only
low-level reactivity is seen when free peptide is analyzed. A
dramatic increase in reactivity is observed when the peptide
is conjugated to bovine serum albumin or thyroglobulin with
titers up to 1.1 x 106. This may be a result of (i) the addition
of a spacer arm for the peptide, thus permitting reaction with
the monoclonal antibody; (ii) the ability of the peptide to
assume the correct conformation when placed on the carrier;
or (iii) more efficient absorption of the peptide-conjugate to
the microtiter plates than of the free peptide.
Monoclonal antibodies from site 2 (1G11-D11 and 951-
C4-G2) and site 3 (611-G10-D3 and 951-D10-B3) both showed
reactivity with peptide 2 (representing residues 83 to 100).
Monoclonal antibodies to antigenic site 1 had no reactivity
with peptide 2. This data suggests that antigenic sites 2 and
3 are closely spaced in M protein and involve residues 83 to
100.
Additional data suggesting the close proximity of antigenic
sites 2 and 3 is derived from time-resolved fluoroimmu-
noassay analysis (Bucher and co-workers, unpublished
results). A large enhancement of reactivity in the time-
resolved fluoroimmunoassay system is seen when monoclo-
nal antibodies from antigenic site 1 are used in combination
with monoclonal antibodies from antigenic site 2 or 3. No
enhancement in reactivity is seen when monoclonal antibod-
ies from antigenic site 2 are used in combination with those
from antigenic site 3. Again this data suggests that antigenic
sites 2 and 3 are closely situated.
At this time, the best interpretation of the data is that
antigenic sites (1A and 1B) lie in close proximity to (or
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FIG. 6. (a) Immunofluorescence (double labeling) visualization of actin (left panel) and M protein (right panel) in influenza virus
(X-53a)-infected CV-1 cell monolayers at 5 h postinfection. In the left panel, actin was visualized with rhodamine-conjugated phalloidin. In
the right panel, M protein was visualized with lGll-D1l monoclonal antibody, followed by the addition of fluorescein-conjugated goat
anti-mouse antibody. Magnification, x400. (b) Immunofluorescence (double labeling) visualization of actin (upper panel) and M protein (lower
panel). Conditions same as for 6a.
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FIG. 7. Immunofluorescence (double labeling) visualization of vaccinia virus proteins (upper panel) and M protein (lower panel) in CV-1
cell monolayers infected with the vaccinia virus recombinant (vP273, containing A/PR/8/34 M-protein gene) at 3 h postinfection. In the upper
panel, visualization was done with rabbit (polyclonal) antisera to vaccinia virus, followed by rhodamine-conjugated goat anti-rabbit antibody.
In the lower panel, visualization was done with 1GIl-D1l monoclonal antibodies to M protein, followed by fluorescein-conjugated goat
anti-mouse antibody. Magnification, x400.
involve) residue 231 and therefore are located near the C
terminus ofM protein (Ml is 252 amino acids in length [44]).
The high level of reactivity of 2E5-C1 (and other narrowly
reactive monoclonal antibodies in site iB) with synthetic
peptides containing an asparagine at position 231 shows a
direct interaction with this site. ELISA reactivity with
synthetic peptide 2 suggests residues 83 to 100 are part of
antigenic sites 2 and 3. Therefore, sites 2 and 3 are located in
the N-terminal half of M protein.
Intracellular localization of M protein. M protein clearly
localizes to the nucleus during influenza virus infection. We
show direct evidence for the presence of M protein in the
nuclei by immunofluorescence during infection both with
influenza virus and a vaccinia virus recombinant containing
the M-protein gene. As demonstrated by infection with the
vaccinia virus recombinant, M protein localizes to the nu-
cleus in the absence of synthesis of other influenza virus
proteins. Synthesis of M protein was far more rapid during
infection with recombinant vaccinia virus vP273, M-protein
staining reached high intensity at 3 h after infection with
vaccinia virus, and a similar intensity of staining was not
seen until 5 h after infection with influenza virus.
The pattern of intracellular and intranuclear localization of
M protein varies from that observed for nucleoprotein. With
M protein, cytoplasmic staining is observed in addition to
nuclear staining. Nuclear staining of M protein is character-
ized by more-intense staining of the nucleoli; nuclear stain-
ing of nucleoprotein is characterized by the absence of stain
from the nucleoli. The higher concentration of M protein in
the nucleoli is of interest in view of the report by Wakefield
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FIG. 8. Immunofluorescence (double labeling) visualization of actin (upper panel) and M protein (lower panel) in CV-1 cell monolayers
infected with vaccinia virus recombinant expressing M protein. Conditions same as for Fig. 7. except rhodamine-conjugated phalloidin was
used for the visualization of actin in the upper panel.
and Brownlee (42) on RNA-binding activity of influenza
virus matrix protein. The nucleoli are the site of ribosomal
assembly and contain high concentrations of rRNA (26).
Other investigators have reported on localization of M
protein to the nucleus during the replicative cycle (14, 16, 24.
28, 30). Maeno and co-workers (24) showed nuclear local-
ization of M protein by immunofluorescence with monospe-
cific sera to purified M protein. Patterson and co-workers
(30) demonstrated the presence of M protein in the nucleus
using immunoelectron microscopy with a monoclonal anti-
body to M protein; however, they did not detect any M
protein in the nucleoli.
During infection with a recombinant vaccinia virus con-
taining a gene encoding MI, Smith and co-workers (39)
found an even distribution of M protein throughout the cell
and did not note more-intense staining of the nucleus. These
investigators performed immunofluorescence analysis for M
protein 6 to 14 h postinfection, a period much later in the
replicative cycle than the 3 h we found optimal for detection
of M protein with infection by the vP273 recombinant
vaccinia virus. Clearly, M protein is capable of transport to
the nucleus in the absence of synthesis of other viral proteins
and therefore must contain a nuclear transport signal; nu-
clear transport of M protein is not blocked during replication
of vaccinia virus recombinants containing the M-protein
gene.
Another feature of intracellular localization ofM protein is
the visualization of actin filaments with monoclonal antibod-
ies to M protein, thus demonstrating the association of M
protein with actin filaments. Interaction of paramyxovirus M
protein and actin has been reported previously (15). These
investigators observed interaction of M protein with actin
immobilized on columns as well as by circular dichroism
analysis. We show direct evidence of M-protein colocaliza-
tion with actin filaments in the cell. This interaction of M
protein with actin may have important implications for the
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assembly of influenza virus and its subsequent maturation by
budding from the cytoplasmic membrane. Interaction of M
protein with actin may also suggest a mechanism for induc-
tion of actin antibodies in association with viral illness (11;
D. R. Tovell, J. S. Huang,I. A. McRobbie, G. A. Lund, and
D. L. J. Tyrrell, Abstr. 6thInt. Congr. Virol., p. 175, 1984).
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